<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="619">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>1/11/2005</approvaldate>
  <actrnumber>ACTRN12605000699662</actrnumber>
  <trial_identification>
    <studytitle>Sandostatin LAR in HCC</studytitle>
    <scientifictitle>Pilot Phase II Study of Sandostatin LAR in Patients with Advanced Hepatocellular Carcinoma to assess toxicity and improve survival</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Australasian Gastro-Intestinal Trials Group: AG0001H</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Hepatocellular Carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Sandostatin LAR for 12 months</interventions>
    <comparator />
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Compliance with treatment</outcome>
      <timepoint>Montly assessments</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Compliance with assessments</outcome>
      <timepoint>Montly assessments</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events, including complications of cirrhosis</outcome>
      <timepoint>Monthly assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Accrual rate</outcome>
      <timepoint>Monthly assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Biopsy rate</outcome>
      <timepoint>Monthly assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Somatostatin receptor positivity rate</outcome>
      <timepoint>Monthly assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subjective patient benefit</outcome>
      <timepoint>Monthly assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>Monthly assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumour response</outcome>
      <timepoint>Monthly assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to progression</outcome>
      <timepoint>Monthly assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Monthly assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Somatostatin receptor status impact on survival</outcome>
      <timepoint>Monthly assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of Sandostatin LAR ®</outcome>
      <timepoint>Monthly assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effects of Sandostatin LAR ® on complications of cirrhosis</outcome>
      <timepoint>Monthly assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Comparison of methods for quantifying somatostatin receptors.</outcome>
      <timepoint>Monthly assessments</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(All of the following): 4.1.1histological OR cytological evidence of hepatocellular carcinoma OR liver imaging suggestive of the diagnosis AND a plasma alpha-fetoprotein over 500 IU/mL. 4.1.2 Hepatocellular carcinoma which is unresectable. 4.1.3patient performance status (WHO) grade 0, 1 or 2.4.1.7women must have a negative pregnancy test prior to treatment; both men and women should have adequate contraception during the course of treatment.4.1.8written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>(None of the following: )4.2.1Previous octreotide treatment for hepatocellular carcinoma4.2.2patient performance status &gt; (WHO) 3 4.2.3peripheral blood white cell count &lt; 2.0 x 109/L, platelet count &lt;50 x 109/L and haemoglobin &lt; 10.0 g/L.4.2.4serum creatinine greater than or equal to 0.15mmol/L; serum bilirubin &gt; 50 micromol/litre; serum albumin &lt; 25 g/L; AST and ALT &gt; 5x institutional upper limit of normal. Patients with Primary Biliary Cirrhosis (PBC) should be classified using Bilirubin levels defined for this patient group in the Childs-Pugh Score (see appendix 7).4.2.5prothrombin ratio (INR) &gt; 2.04.2.6any inter-current illness that may significantly interfere with safe administration of Sandostatin LAR® or end-point evaluation; including refractory severe encephalopathy, symptomatic gallstone disease (either cholecystolithiasis or choledocholithiasis).4.2.7Treatment with somatostatin for other reasons4.2.8Concurrent anti-tumour treatment for HCC4.2.9pregnant women4.2.10previous malignancy within the last 5 years other than curatively resected non-melanoma skin cancer or carcinoma of the uterine cervix.4.2.11known reaction to the study drug4.2.12HIV positive patients4.2.13uncontrolled ascites requiring paracentesis within 4 weeks4.2.14variceal bleeding in the last month4.2.15prior radiation therapy to the only evaluable site of disease4.2.16refusal to give informed consent to participate in the study4.2.17Child-Pugh class C cirrhosis, (for patients with PBC use the adjusted bilirubin levels to classify the patient).4.2.18patients who are rendered artificially eligible by the administration of blood product support.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>6/04/2001</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Site - Investigator Initiated</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis Educational Grant</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>AGITG</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jonathon Cebon</name>
      <address>Ludwig Institute of Cancer Research
Austin and Repatriation Medical Centre (A&amp;RMC)
Melbourne VIC 3084</address>
      <phone>+61 2 95625334</phone>
      <fax />
      <email>jonathan.cebon@ludwig.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Burcu Cakir</name>
      <address>Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 95625334</phone>
      <fax>+61 2 95625094</fax>
      <email>bcakir@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>